Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a EoE Trial Data, Highlighting Strong Symptom Response

summarizeSummary

Eupraxia Pharmaceuticals reported positive 24-week symptom data from its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis, showing strong clinical remission rates and a favorable safety profile for EP-104GI.

check_boxKey Events

• Positive Symptom Data from Highest Dose Cohort

  Patients in the highest dose cohort (n=3) of the Phase 1b/2a RESOLVE trial achieved an average 4-point reduction in symptom scores at 24 weeks, exceeding the 3-point threshold for clinical remission.

• High Clinical Remission Rates Maintained

  Pooled data from dose cohorts 4-9 indicated that 76% (13/17) of patients maintained clinical remission at 24 weeks, and 67% (6/9) maintained it at 52 weeks.

• Improved Drug Delivery Re-establishes Dose-Response

  The adoption of larger 19-gauge catheters for the 6 mg/site dose (Cohort 8b) significantly improved outcomes, including SDI reduction and peak eosinophil reduction, compared to previous catheter use, re-establishing the dose-response relationship.

• Strong Safety and Tolerability Profile

  Over 220 patient-months of follow-up across 31 patients reported no Serious Adverse Events (SAEs) or cases of oropharyngeal candidiasis, a common adverse event with oral steroids.

auto_awesomeAnalysis

Eupraxia Pharmaceuticals announced positive 24-week symptom data from the highest dose cohort of its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis (EoE). The data shows a meaningful symptom response and high rates of clinical remission, which is critical for a clinical-stage biotechnology company. The improved drug delivery with new catheters and the continued strong safety profile further de-risk the EP-104GI program and provide a positive signal for the ongoing placebo-controlled Phase 2b trial, with top-line data anticipated in Q3 2026. This positive clinical update follows recent news of an extended cash runway and increased insider ownership, creating a favorable near-term narrative for the company.